Expertise in
5
conditions

Marc Van Ranst

Leuven, VLG, BE 
Expertise in
5
conditions
Leuven, VLG, BE 
OverviewLocationsClinical Research

Overview

Marc Van Ranst practices in Leuven, Belgium. Mr. Van Ranst is highly rated in 5 conditions, according to our data. His top areas of expertise are Hantavirus Pulmonary Syndrome, Hantavirus Infection, Severe Acute Respiratory Syndrome (SARS), and Parainfluenza.

His clinical research consists of co-authoring 212 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Leuven, VLG 3000, Belgium
Other Locations
Gent, VLG, Belgium
Bonheiden, VLG 2820, Belgium
Brussels, BRU, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II Study of a Primary Dose of Investigational RSV Maternal Vaccine, Given Alone or With Boostrix, With a 2nd Dose Investigational RSV Maternal Vaccine
A Phase II Study of a Primary Dose of Investigational RSV Maternal Vaccine, Given Alone or With Boostrix, With a 2nd Dose Investigational RSV Maternal Vaccine
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Biological, Drug
Study Drugs: RSVPreF3, Boostrix-ex-US, Boostrix-US
Study Phase: Phase 2
A Phase 2b, Open-label, Multi-center, Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 Older Adults (OA) Investigational Vaccine Administered Intramuscularly 18 Months Post-Dose 2 in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study
A Phase 2b, Open-label, Multi-center, Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 Older Adults (OA) Investigational Vaccine Administered Intramuscularly 18 Months Post-Dose 2 in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study
Enrollment Status: Completed
Publish Date: June 29, 2022
Intervention Type: Biological
Study Drug: RSVPreF3 OA investigational vaccine
Study Phase: Phase 2
View 1 Less Clinical Trial

212 Total Publications

SDS-EDTA-treated chromatography paper strips for sampling and transportation of monkeypox virus, varicella zoster virus and herpes simplex 1 and 2 viruses.
SDS-EDTA-treated chromatography paper strips for sampling and transportation of monkeypox virus, varicella zoster virus and herpes simplex 1 and 2 viruses.
Journal: Virology journal
Published: May 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Van Ranst's expertise for a condition
ConditionClose
    View All 39 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile